Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imsidolimab in Generalized Pustular Psoriasis
NCT05352893Phase 3Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of imsidolimab in generalized pustular psoriasis (GPP), sponsored by Vanda Pharmaceuticals Inc.. Started Apr 2022; status: completed.
02
Drugs
imsidolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT05352893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05352893.